Is Biogen (BIIB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.2% / 30% | 14.1% / 30% | 6.9% / 30% | 1.26% / 5% | ✓ HALAL |
| DJIM | 24.2% / 33% | 14.1% / 33% | 6.9% / 33% | 1.26% / 5% | ✓ HALAL |
| MSCI | 22.3% / 33% | 13.0% / 33% | 6.3% / 33% | 1.26% / 5% | ✓ HALAL |
| S&P | 24.2% / 33% | 14.1% / 33% | 6.9% / 33% | 1.26% / 5% | ✓ HALAL |
| FTSE | 22.3% / 33% | 13.0% / 33% | 6.3% / 50% | 1.26% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 78.9% | |
| Operating Margin | 19.6% | |
| Net Margin | 13.1% | |
| Return on Equity (ROE) | 7.4% | |
| Return on Assets (ROA) | 6.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2.2B |
| Free Cash Flow | $2.0B |
| Total Debt | $6.6B |
| Debt-to-Equity | 36.5 |
| Current Ratio | 2.7 |
| Total Assets | $29.4B |
Price & Trading
| Last Close | $191.06 |
| 50-Day MA | $184.80 |
| 200-Day MA | $158.20 |
| Avg Volume | 1.3M |
| Beta | 0.1 |
|
52-Week Range
$110.04
| |
About Biogen (BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Purification Calculator
As a halal stock with 1.26% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Biogen (BIIB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Biogen is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Biogen's debt ratio?
Biogen's debt ratio is 24.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.3%.
Does Biogen require dividend purification?
Yes, Biogen has an impermissible income ratio of 1.26%, which means 1.26% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Biogen's key financial metrics?
Biogen has a market capitalization of $27.0B, trailing P/E ratio of 20.9, and revenue of $9.9B. The company maintains a gross margin of 78.9% and a net margin of 13.1%. Return on equity stands at 7.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.